Equity intelligence report • July 05, 2026
Moderna is navigating a challenging financial landscape marked by a $514 million net loss in Q1 2022, despite recording $6.1 billion in revenue driven by COVID-19 vaccine sales. The company faces difficulties with dwindling investor confidence, a significant decline in its stock, and increasing R&D costs, raising concerns about its financial stability amid ongoing uncertainties surrounding vaccine demand. Additionally, Moderna is under scrutiny for its regulatory practices and is dealing with legal challenges, including a lawsuit from BioNTech. The company continues to develop new booster shots, including a modified vaccine targeting Omicron subvariants, amidst these ongoing challenges.
Click a month on the chart to update the report below.
